FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.317,55 +231,75 (+0,61%) Nasdaq
15.971,58 +359,82 (+2,30%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,82 +0,25 (+0,30%) Bitcoin EUR
59.814,49 -537,19 (-0,89%)
Genmab A/S (GMAB.CO)
| Chiusura precedente | 1.915,50 |
| Aperto | 1.919,50 |
| Denaro | 1.954,50 x N/D |
| Lettera | 1.960,00 x N/D |
| Min-Max giorno | 1.919,50 - 1.969,00 |
| Intervallo di 52 settimane | 1.825,00 - 2.939,00 |
| Volume | |
| Media Volume | 129.392 |
| Capitalizzazione | 126,757B |
| Beta (5 anni mensile) | 0,78 |
| Rapporto PE (ttm) | 29,58 |
| EPS (ttm) | 66,08 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 2.679,62 |
GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; September 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 7,609 restricted stock units and 7,873 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of gran
- GlobeNewswire
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Company Announcement TEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the European Commission is supported by data from the pivotal phase 1/2 EPCORE™ NHL-1 clinical trial, which demonstrated 62 percent overall response rate, 39 percent complete response, and 1
- GlobeNewswire
EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Media Release Subcutaneous EPKINLYTM (epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapyApproval based on results of EPCORETM NHL-3 and EPCORETM NHL-1 clinical trials, evaluating EPKINLY in patients with certain types of R/R LBCLLBCL is a common form of non-Hodgkin’s lymphoma (NHL) and currently has limited treatment options, parti
